Filter
Period
Filter by
recent search
Showing: 1 – 05 of 153 Regulated Information
14 December 2022
14 December 2022
LinkedIn
Facebook
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
PARIS, FRANCE, 23 December 2022 – The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application for palovarotene, an investigational treatment for the reduction of new abnormal bone formation (heterotopic ossification) in people…
09 December 2022
09 December 2022
LinkedIn
Voting rights on 30 November 2022
This article or press release has no online content. Please download the associated documents for more information.
10 November 2022
10 November 2022
LinkedIn
Voting rights on 31 October 2022
This article or press release has no online content. Please download the associated documents for more information.
27 October 2022
27 October 2022
LinkedIn
Ipsen delivers strong sales growth in the first nine months of 2022 and confirms its full-year guidance
Paris (France), 27 October 2022
10 October 2022
10 October 2022
LinkedIn
Voting rights on 30 September 2022
This article or press release has no online content. Please download the associated documents for more information.